Kymera Therapeutics Inc (KYMR) - Net Assets
Based on the latest financial reports, Kymera Therapeutics Inc (KYMR) has net assets worth $1.54 Billion USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.67 Billion) and total liabilities ($129.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check KYMR tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.54 Billion |
| % of Total Assets | 92.25% |
| Annual Growth Rate | N/A |
| 5-Year Change | 243.68% |
| 10-Year Change | N/A |
| Growth Volatility | 49.31 |
Kymera Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Kymera Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See KYMR defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Kymera Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Kymera Therapeutics Inc from 2018 to 2025. For live valuation and market cap data, see Kymera Therapeutics Inc (KYMR) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $1.58 Billion | +89.04% |
| 2024-12-31 | $835.62 Million | +111.56% |
| 2023-12-31 | $394.97 Million | -19.42% |
| 2022-12-31 | $490.15 Million | +6.64% |
| 2021-12-31 | $459.64 Million | +61.91% |
| 2020-12-31 | $283.89 Million | +481.54% |
| 2019-12-31 | $-74.41 Million | -116.07% |
| 2018-12-31 | $-34.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kymera Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 103075100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $8.00K | 0.00% |
| Other Comprehensive Income | $1.80 Million | 0.11% |
| Other Components | $2.64 Billion | 167.37% |
| Total Equity | $1.58 Billion | 100.00% |
Kymera Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Kymera Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
$6.10 Billion |
|
MERUS N.V. EO -09
F:2GH
|
$6.11 Billion |
|
PTC Therapeutics Inc
NASDAQ:PTCT
|
$6.11 Billion |
|
Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság
F:MGYB
|
$6.11 Billion |
|
Nice Ltd ADR
NASDAQ:NICE
|
$6.10 Billion |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
$6.09 Billion |
|
JB Hi-Fi Ltd
AU:JBH
|
$6.09 Billion |
|
Huaibei Mining Holdings Co Ltd
SHG:600985
|
$6.09 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kymera Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 835,619,000 to 1,579,664,000, a change of 744,045,000 (89.0%).
- Net loss of 311,400,000 reduced equity.
- New share issuances of 928,901,000 increased equity.
- Other comprehensive income increased equity by 3,285,000.
- Other factors increased equity by 123,259,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-311.40 Million | -19.71% |
| Share Issuances | $928.90 Million | +58.8% |
| Other Comprehensive Income | $3.29 Million | +0.21% |
| Other Changes | $123.26 Million | +7.8% |
| Total Change | $- | 89.04% |
Book Value vs Market Value Analysis
This analysis compares Kymera Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-0.77 | $89.90 | x |
| 2019-12-31 | $-1.67 | $89.90 | x |
| 2020-12-31 | $6.37 | $89.90 | x |
| 2021-12-31 | $9.58 | $89.90 | x |
| 2022-12-31 | $9.09 | $89.90 | x |
| 2023-12-31 | $6.77 | $89.90 | x |
| 2024-12-31 | $11.14 | $89.90 | x |
| 2025-12-31 | $18.72 | $89.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kymera Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -794.39%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.10x
- Recent ROE (-19.71%) is below the historical average (-19.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.02 Million |
| 2019 | 0.00% | -1407.36% | 0.03x | 0.00x | $-33.85 Million |
| 2020 | -16.06% | -133.96% | 0.07x | 1.72x | $-73.98 Million |
| 2021 | -21.80% | -137.60% | 0.12x | 1.32x | $-146.18 Million |
| 2022 | -31.58% | -330.60% | 0.08x | 1.23x | $-203.82 Million |
| 2023 | -37.21% | -186.99% | 0.14x | 1.46x | $-186.46 Million |
| 2024 | -26.79% | -475.57% | 0.05x | 1.17x | $-307.42 Million |
| 2025 | -19.71% | -794.39% | 0.02x | 1.10x | $-469.37 Million |
Industry Comparison
This section compares Kymera Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kymera Therapeutics Inc (KYMR) | $1.54 Billion | 0.00% | 0.08x | $6.10 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CR… Read more